Los Angeles Capital Management LLC Acquires 47,563 Shares of Inspire Medical Systems, Inc. (NYSE:INSP)

Los Angeles Capital Management LLC raised its holdings in Inspire Medical Systems, Inc. (NYSE:INSP) by 110.7% in the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 90,542 shares of the company’s stock after purchasing an additional 47,563 shares during the period. Los Angeles Capital Management LLC owned approximately 0.30% of Inspire Medical Systems worth $16,785,000 at the end of the most recent quarter.

A number of other institutional investors have also recently bought and sold shares of the business. Y Intercept Hong Kong Ltd bought a new stake in Inspire Medical Systems in the 4th quarter valued at about $461,000. Wealthspire Advisors LLC acquired a new position in shares of Inspire Medical Systems in the 4th quarter valued at approximately $402,000. First Horizon Advisors Inc. raised its position in shares of Inspire Medical Systems by 885.7% in the 4th quarter. First Horizon Advisors Inc. now owns 138 shares of the company’s stock valued at $26,000 after buying an additional 124 shares in the last quarter. Ieq Capital LLC raised its position in shares of Inspire Medical Systems by 781.5% in the 4th quarter. Ieq Capital LLC now owns 21,095 shares of the company’s stock valued at $3,911,000 after buying an additional 18,702 shares in the last quarter. Finally, TimesSquare Capital Management LLC acquired a new position in shares of Inspire Medical Systems in the 4th quarter valued at approximately $80,419,000. Institutional investors own 94.91% of the company’s stock.

Analyst Upgrades and Downgrades

Several brokerages have recently commented on INSP. Stifel Nicolaus dropped their target price on shares of Inspire Medical Systems from $200.00 to $190.00 and set a “hold” rating for the company in a research report on Tuesday, January 21st. Wells Fargo & Company dropped their target price on shares of Inspire Medical Systems from $198.00 to $195.00 and set an “equal weight” rating for the company in a research report on Tuesday, February 11th. Royal Bank of Canada restated an “outperform” rating and issued a $260.00 target price on shares of Inspire Medical Systems in a research report on Tuesday, February 11th. Piper Sandler dropped their target price on shares of Inspire Medical Systems from $260.00 to $233.00 and set an “overweight” rating for the company in a research report on Monday, February 10th. Finally, KeyCorp restated an “overweight” rating and issued a $234.00 target price (down from $236.00) on shares of Inspire Medical Systems in a research report on Friday, January 24th. Three analysts have rated the stock with a hold rating and eight have issued a buy rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $228.82.

Insiders Place Their Bets

In other news, insider Randy Ban sold 25,584 shares of the company’s stock in a transaction on Thursday, February 13th. The shares were sold at an average price of $183.50, for a total value of $4,694,664.00. Following the sale, the insider now directly owns 7,259 shares of the company’s stock, valued at approximately $1,332,026.50. This represents a 77.90 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, CTO John Rondoni sold 583 shares of the company’s stock in a transaction on Tuesday, February 11th. The shares were sold at an average price of $170.49, for a total transaction of $99,395.67. Following the completion of the sale, the chief technology officer now directly owns 10,424 shares in the company, valued at approximately $1,777,187.76. This represents a 5.30 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 26,225 shares of company stock valued at $4,806,530 in the last ninety days. 4.10% of the stock is currently owned by insiders.

Inspire Medical Systems Price Performance

INSP stock opened at $184.76 on Wednesday. Inspire Medical Systems, Inc. has a 1 year low of $123.00 and a 1 year high of $257.40. The stock has a market cap of $5.48 billion, a price-to-earnings ratio of 106.80, a P/E/G ratio of 2.86 and a beta of 1.32. The company has a 50 day simple moving average of $187.75 and a 200 day simple moving average of $193.21.

Inspire Medical Systems (NYSE:INSP) last posted its earnings results on Monday, February 10th. The company reported $1.15 earnings per share for the quarter, topping analysts’ consensus estimates of $0.74 by $0.41. Inspire Medical Systems had a net margin of 6.67% and a return on equity of 8.19%. On average, equities research analysts anticipate that Inspire Medical Systems, Inc. will post 2.16 EPS for the current fiscal year.

Inspire Medical Systems Profile

Inspire Medical Systems, Inc, a medical technology company, focuses on the development and commercialization of minimally invasive solutions for patients with obstructive sleep apnea (OSA) in the United States and internationally. The company offers Inspire system, a neurostimulation technology that provides a safe and effective treatment for moderate to severe OSA.